In summary, this study demonstrated that the dcHGT NPs mitigated the AD dysfunction via two collaborative progressive methods: 1) inhibiting Aβ aggregation and facilitating Aβ disaggregation to modulate Aβ‐related inflammation and neuronal damage and 2) the alleviation of Aβ‐related inflammation and AChE‐inhibited effect further synergistically adjusted acetylcholine imbalance, which inhibit the subsequent pathological cascades as a promising high‐efficiency nanoplatform for the combination therapy of AD. This evidence concerns the gene ACHE and Alzheimer disease.